Teaser: Meet Juan-Valdez Cappuccino

Hello, my name is Juan Valdez Cappuccino here with BGP Medical Strategy Team and together with one of your science expert colleagues here at BGP, we're true believers in connecting patients with Alzheimer's disease to the disease-modifying treatment that they need. We know that currently they are facing many hurdles, specifically diagnosis, they are long waiting times to see a specialist or to get a PET scan, but there are certain things in the field that are moving quite quickly, I would say, that are bringing hope. Things like AI-based imaging interpretation, AI-based diagnosis, blood-based biomarkers, which have recently been mentioned in the FDA's Peripheral and Central Nervous System Advisory Committee, meeting that happened a few weeks ago, as needed and desired to be used in clinical practice. This space has been evolving rapidly and will continue to evolve rapidly. To date, there are no FDA-approved blood-based biomarkers, but that could change in any moment. So together, our BGP Medical Team and KX Advisors, team's partners together to initiate a series of reports, the first being an overview of current blood-based biomarkers for Alzheimer's disease diagnosis and emerging trends. Because we truly believe that in the future, there might be a world where blood-based biomarker testing comes routine, together or in par with your yearly lipid panel screen, for example. Or another scenario could be that there are different treatments for different stages of Alzheimer's disease, and blood-based biomarkers could help treatment decisions for which treatment is best at each stage, such as they do today in oncology. At the moment, these biomarkers still require significant education among physicians and patients to aid their navigation and communication, how to use them, when to use them. And that's why we're here. Our report doesn't try to predict who will be the winner in the race, but it's clear that these blood-based biomarkers will eventually garner FDA approval and pay our coverage eventually, and that's important. So here at BGP and KX, we look forward to supporting our clients in the efforts to continue to break down these barriers and get patients the life-altering treatments that they deserve.